ES2521841A1 - Procedure for diagnosis and prognosis of chronic kidney disease in a human subject (Machine-translation by Google Translate, not legally binding) - Google Patents

Procedure for diagnosis and prognosis of chronic kidney disease in a human subject (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2521841A1
ES2521841A1 ES201330663A ES201330663A ES2521841A1 ES 2521841 A1 ES2521841 A1 ES 2521841A1 ES 201330663 A ES201330663 A ES 201330663A ES 201330663 A ES201330663 A ES 201330663A ES 2521841 A1 ES2521841 A1 ES 2521841A1
Authority
ES
Spain
Prior art keywords
chronic kidney
kidney disease
prognosis
diagnosis
translation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330663A
Other languages
Spanish (es)
Other versions
ES2521841B1 (en
Inventor
María POSADA AYALA
Gloria ÁLVAREZ LLAMAS
María Eugenia GONZÁLEZ BARDERAS
Fernando VIVANCO MARTÍNEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Original Assignee
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority to ES201330663A priority Critical patent/ES2521841B1/en
Publication of ES2521841A1 publication Critical patent/ES2521841A1/en
Application granted granted Critical
Publication of ES2521841B1 publication Critical patent/ES2521841B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Procedure and kit for diagnosis and prognosis of chronic kidney disease and cardiovascular disease associated with chronic kidney disease in a human subject, comprising determining in a sample the concentrations of at least one of the compounds selected from the group consisting of 5-oxoproline, glutamate, guanidoacetate, alpha-phenylacetylglutamine, taurine, trimethylamine N-oxide (tmno), homocysteine, leucine, threonine and citrate, determine if the values of these concentrations are higher or lower than the reference values of healthy patients. (Machine-translation by Google Translate, not legally binding)

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

en una primera fase de descubrimiento (“discovery”) (15 pacientes) como en la segunda fase de validación (16 pacientes). Igualmente se reclutaron un total de 15 individuos sanos en la fase de descubrimiento y 15 en la de validación, sin diabetes, hipertensión, enfermedad renal o inflamatoria y sin tratamiento farmacológico que presente interferencia in a first phase of discovery ("discovery") (15 patients) and in the second phase of validation (16 patients). Likewise, a total of 15 healthy individuals were recruited in the discovery phase and 15 in the validation phase, without diabetes, hypertension, renal or inflammatory disease and without drug treatment that presents interference

5 con las variables estudiadas. Se realizó un análisis RMN con los pacientes 1-15 y una validación por espectrometría de masas con los pacientes 16-31. Este grupo se equiparó en edad y sexo con el grupo de individuos sanos (controles). Se muestran las características de los pacientes. 5 with the variables studied. An NMR analysis was performed with patients 1-15 and a validation by mass spectrometry with patients 16-31. This group was matched in age and sex with the group of healthy individuals (controls). The characteristics of the patients are shown.

10 TABLA 1 10 TABLE 1

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

Claims (1)

imagen1image 1 imagen2image2
ES201330663A 2013-05-08 2013-05-08 Diagnostic procedure and prognosis of chronic kidney disease in a human subject Expired - Fee Related ES2521841B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201330663A ES2521841B1 (en) 2013-05-08 2013-05-08 Diagnostic procedure and prognosis of chronic kidney disease in a human subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330663A ES2521841B1 (en) 2013-05-08 2013-05-08 Diagnostic procedure and prognosis of chronic kidney disease in a human subject

Publications (2)

Publication Number Publication Date
ES2521841A1 true ES2521841A1 (en) 2014-11-13
ES2521841B1 ES2521841B1 (en) 2015-09-09

Family

ID=51866519

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330663A Expired - Fee Related ES2521841B1 (en) 2013-05-08 2013-05-08 Diagnostic procedure and prognosis of chronic kidney disease in a human subject

Country Status (1)

Country Link
ES (1) ES2521841B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094813A1 (en) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. Medicine for kidney disorder
ES2300856T3 (en) * 2003-12-19 2008-06-16 Bio3 Research S.R.L. THE USE OF CYSTERINE OR CYSTEINE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS CAUSED BY HEMODIALISIS IN PATIENTS WITH ACUTE OR CHRONIC RENAL DISEASE.
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300856T3 (en) * 2003-12-19 2008-06-16 Bio3 Research S.R.L. THE USE OF CYSTERINE OR CYSTEINE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS CAUSED BY HEMODIALISIS IN PATIENTS WITH ACUTE OR CHRONIC RENAL DISEASE.
WO2005094813A1 (en) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. Medicine for kidney disorder
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUEWALL JL. et al. 5-Oxoproline (pyroglutamic) acidosis associated with chronic acetaminophen use. Baylor University Medical Center Proceedings. 2010. Vol. 23(1), páginas 19-20, todo el documento. *
JAMISON RL. et al. Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease. Journal American Medical Association. 2007. Vol. 298(10), páginas: 1163-1170, todo el documento. *
MOUSTAPHA A. et al. Prospective Study of Hyperhomocysteinemia as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. Circulation. 1998. Vol. 97, páginas: 138-141, todo el documento. *

Also Published As

Publication number Publication date
ES2521841B1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
Simińska et al. Amino acid profiling as a method of discovering biomarkers for early diagnosis of cancer
Tsuruoka et al. Capillary electrophoresis‐mass spectrometry‐based metabolome analysis of serum and saliva from neurodegenerative dementia patients
EA201792497A1 (en) ANTIBODIES TO GITR FOR DIAGNOSIS OF MALIGNANT TUMOR
MX2016000293A (en) Biomarkers of autism spectrum disorder.
EA202191666A1 (en) ANTIBODIES TO IL-27 AND THEIR USE
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
ES2521841A1 (en) Procedure for diagnosis and prognosis of chronic kidney disease in a human subject (Machine-translation by Google Translate, not legally binding)
RU2014113841A (en) METHOD FOR EARLY DIAGNOSTICS OF ENDOGENOUS INTOXICATION
WO2015028974A3 (en) Polyp recurrence
WO2015193738A3 (en) Methods and biomarkers for analysis of colorectal cancer
UA108678U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA108369U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA110747U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA110719U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA109990U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
Agarwal et al. Evaluation of the tCho and β-catenin concentration with different molecular biomarkers in breast cancer patients
UA110730U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA110681U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA108626U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA111762U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA110698U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA111399U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
UA109449U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT
ES2538552A1 (en) Monoclonal antibody that recognizes enteromyxum scophthalmi, procedure and diagnostic kit for turbot enteromyxosis (Machine-translation by Google Translate, not legally binding)
UA111286U (en) METHOD OF DIAGNOSTICS OF OSTEOPOROSIS DEVELOPMENT

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2521841

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150909

FD2A Announcement of lapse in spain

Effective date: 20230926